Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Strattera

Eli Lilly HQ

Prospects for Lilly’s Verzenio hit by botched lung cancer trial

The CDK 4/6 inhibitor failed to improve overall survival in a late-stage study

Eli Lilly HQ

Lilly axes 3,500 jobs in $500m-a-year cost-cutting drive

US drug maker to slash its workforce by 8.5%

Roche Basel Switzerland

UK is first to receive Roche’s rare lung cancer drug

Alecensa made available under MHRA's early access scheme

Eli Lilly HQ

Lilly wins on appeal in Alimta vitamin regimen dispute

UK Supreme Court rules in its favour over Actavis

- PMLiVE

Shire claims FDA approval for slow-cooked ADHD drug

Mydayis will reach the US market in the third quarter of the year

Lilly joins Personal Connected Health Alliance

Samsung, AT&T and IPSOS Healthcare also sign up

Eli Lilly HQ

Lilly set to head to regulators with CGRP migraine drug

Gathers three positive late-stage trials of galcanezumab as it chases Amgen

MHRA launches medicines regulation blog as Brexit looms

MedRegs will provides insight into its latest regulatory thinking

- PMLiVE

Lilly pilots enhanced online trial information

Company aims to aid comprehension of the informed consent process

Eli Lilly HQ

Lilly to buy migraine drug developer CoLucid for $960m

Deal revolves around lasmiditan, which the firm out-licensed in 2005

Eli Lilly HQ

Lilly taps AstraZeneca for another anti-amyloid drug

MEDI1814 could potentially slow the progression of Alzheimer's

- PMLiVE

New Jardiance label could boost sales by $1.7bn, says analyst

Diabetes treatment can reduce the risk of cardiovascular death in type 2 patients

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links